Results 31 to 40 of about 6,421 (186)

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions [PDF]

, 2022
Nirmatrelvir-ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. This article provides advice to clinicians regarding recognition of medications likely to interact with NMV/r and suggests approaches to managing
Back, D., Boffito, M., Boyle, A., Burger, D., Flexner, C., Gibbons, S., Khoo, S., Kuritzkes, D. R., Marra, F., Marzolini, C., Pozniak, A., Waters, L.   +11 more
core   +1 more source

Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies

Frontiers in Immunology, 2023
The coronavirus disease 2019 (COVID-19) pandemic has caused a significant burden of morbidity and mortality worldwide, with solid organ transplant recipients (SOTRs) being particularly vulnerable.
Yangming Tang, Yue Li, Turun Song
doaj   +1 more source

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration.
Qinqin Zhao, Bei Zheng, Bing Han, Pinpin Feng, Zhongni Xia, Hong Jiang, Yin Ying, Jun Zhu, Cheng Fei, Junlei Xiang, Lingli Shen, Qiliang Luo, Yinhuan Wu, Ayiguzhali Wusiman, Chuanwei Xin, Meiling Zhang, Gonghua Li, Xiang Li   +17 more
doaj   +1 more source

PRELIMINARY ANALYSIS ON EFFICACY OF RITONAVIR-BOOSTED NIRMATRELVIR ON DISEASE PROGRESSION AMONG HIGH-RISK HOSPITALISED COVID-19 PATIENTS: A RETROSPECTIVE CASE-CONTROL STUDY

International Journal of Infectious Diseases, 2023
Intro: Ritonavir-boosted nirmatrelvir has shown efficacy in reducing the rate of hospitalisation and 28-day mortality among unvaccinated populations with COVID-19.
S.P. Lee, C.H. Chuah, W.Y. Mak, J.W. Tan, J.N. Lee, F.N. Bidin, K.N. Leong, P.S. Wong, T.S. Chow   +8 more
doaj   +1 more source

The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19

Journal of International Medical Research
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong, Dan Shen, Jinfang Shi, Ye Jiang, Jie Gao   +4 more
doaj   +1 more source

Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System

Infectious Diseases and Therapy
Introduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients nationally. Methods We conducted a retrospective cohort study among
Haley J. Appaneal, Kerry L. LaPlante, Vrishali V. Lopes, Catherine Martin, Laura Puzniak, Timothy L. Wiemken, Evan J. Zasowski, John M. McLaughlin, Aisling R. Caffrey   +8 more
doaj   +1 more source

Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study

Annals of Medicine
Background The effectiveness of nirmatrelvir–ritonavir has mainly been shown in non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19).
Xiaobo Han, Chenglong Li, Xin Yuan, Junchang Cui, Zhihai Han, Jiguang Meng, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Wei Chen, Junchen Xiong, Dahui Zhao, Xinxin Zhang, Xinjie Han, Haibo Cheng, Zhongkuo Yu, Yinghan Shi, Wuxiang Xie, Lixin Xie   +24 more
doaj   +1 more source

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19

Frontiers in Pharmacology, 2023
Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with COVID-19 infection because of lack of evidence of safety.Objectives ...
Jiayue Lu, Hong Cai, Yujun Hao, Zhang Lin, Shang Liu, Yaping Zhan, Li Ding, Meilan Huang, Zhenyuan Li, Lan Xu, Xiujuan Yan, Li Yang, He Zhang, Wei Zhang, Li Zhao, Junli Zhao, Ting Wang, Leyi Gu   +17 more
doaj   +1 more source

VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 [PDF]

, 2023
To the Editor: Cao and colleagues (Feb. 2 issue)1 report that the oral antiviral agent VV116 was noninferior to nirmatrelvir–ritonavir in alleviating Covid-19–related ...
Fleming, Thomas R, Lin, Dan-Yu
core   +2 more sources

Severe COVID-19 caused by persistent SARS-CoV-2 infection successfully treated with dual direct acting antivirals [PDF]

, 2022
We report the use of combination therapy with remdesivir and nirmatrelvir/ritonavir (Paxlovid) in successfully treating severe, chronic COVID-19 caused by persistent SARS-CoV-2 infection over 4 months.
Snell, Luke Blagdon, Bakrania, Prijay, Williams, Tom G.S., Tam, Jerry, Da Silva Fontoura, Dayana, Shaw, Emily, Daunt, Anna, Edgeworth, Jonathan, Hemsley, Carolyn J., Fields, Paul, Agarwal, Sangita, Lams, Boris, Cahill, Helen, Milligan, Iain, Botgros, Alina, Nebbia, Gaia, Douthwaite, Sam, Aarons, Emma J.   +17 more
core